Literature DB >> 9880554

Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties.

M T Kaartinen1, A Pirhonen, A Linnala-Kankkunen, P H Mäenpää.   

Abstract

Osteopontin, a major noncollagenous bone protein, is an in vitro and in vivo substrate of tissue transglutaminase, which catalyzes formation of cross-linked protein aggregates. The roles of the enzyme and the polymeric osteopontin are presently not fully understood. In this study we provide evidence that transglutaminase treatment significantly increases the binding of osteopontin to collagen. This was tested with an enzyme-linked immunosorbent assay. The results also show that this increased interaction is clearly calcium-dependent and specific to osteopontin. In dot blot overlay assay 1 microgram of collagen type I was able to bind 420 ng of in vitro prepared and purified polymeric osteopontin and only 83 ng of monomeric osteopontin, indicating that the transglutaminase treatment introduces a 5-fold amount of osteopontin onto collagen. Assays using a reversed situation showed that the collagen binding of the polymeric form of osteopontin appears to be dependent on its conformation in solution. Circular dichroism analysis of monomeric and polymeric osteopontin indicated that transglutaminase treatment induces a conformational change in osteopontin, probably exposing motives relevant to its interactions with other extracellular molecules. This altered collagen binding property of osteopontin may have relevance to its biological functions in tissue repair, bone remodeling, and collagen fibrillogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880554     DOI: 10.1074/jbc.274.3.1729

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Separation of newly formed bone from older compact bone reveals clear compositional differences in bone matrix.

Authors:  Ronald J Midura; Sharon B Midura; Xiaowei Su; Jeffrey P Gorski
Journal:  Bone       Date:  2011-09-18       Impact factor: 4.398

2.  Decreased Mechanical Strength and Collagen Content in SPARC-Null Periodontal Ligament Is Reversed by Inhibition of Transglutaminase Activity.

Authors:  Jessica Trombetta-eSilva; Emilie A Rosset; R Glenn Hepfer; Gregory J Wright; Catalin Baicu; Hai Yao; Amy D Bradshaw
Journal:  J Bone Miner Res       Date:  2015-05-10       Impact factor: 6.741

3.  Importance of phosphorylation for osteopontin regulation of biomineralization.

Authors:  A Gericke; C Qin; L Spevak; Y Fujimoto; W T Butler; E S Sørensen; A L Boskey
Journal:  Calcif Tissue Int       Date:  2005-07-14       Impact factor: 4.333

4.  Post-translational modification of osteopontin: effects on in vitro hydroxyapatite formation and growth.

Authors:  Adele L Boskey; Brian Christensen; Hayat Taleb; Esben S Sørensen
Journal:  Biochem Biophys Res Commun       Date:  2012-02-10       Impact factor: 3.575

Review 5.  Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation.

Authors:  A O'Regan; J S Berman
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

6.  Transglutaminase-mediated oligomerization promotes osteoblast adhesive properties of osteopontin and bone sialoprotein.

Authors:  Jennifer Forsprecher; Zhemeng Wang; Harvey A Goldberg; Mari T Kaartinen
Journal:  Cell Adh Migr       Date:  2011-01-01       Impact factor: 3.405

7.  Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells.

Authors:  Kristen A Johnson; Monika Polewski; Robert A Terkeltaub
Journal:  Circ Res       Date:  2008-01-17       Impact factor: 17.367

Review 8.  Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI.

Authors:  Mahipal Singh; Cerrone R Foster; Suman Dalal; Krishna Singh
Journal:  J Mol Cell Cardiol       Date:  2009-06-30       Impact factor: 5.000

9.  Use of tissue transglutaminase and fibronectin to influence osteoblast responses to tricalcium phosphate scaffolds.

Authors:  M D Ball; D O'Connor; A Pandit
Journal:  J Mater Sci Mater Med       Date:  2008-08-14       Impact factor: 3.896

10.  The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice.

Authors:  Muhammad Muddasir Qureshi; Warren C McClure; Nicole L Arevalo; Rick E Rabon; Benjamin Mohr; Swapan K Bose; Joe M McCord; Brian S Tseng
Journal:  J Diet Suppl       Date:  2010-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.